BrainsWay Ltd. (NASDAQ:BWAY) Sees Large Decrease in Short Interest

BrainsWay Ltd. (NASDAQ:BWAY) was the target of a significant decline in short interest in June. As of June 30th, there was short interest totalling 36,300 shares, a decline of 14.8% from the June 15th total of 42,600 shares. Based on an average trading volume of 61,400 shares, the short-interest ratio is presently 0.6 days.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in BWAY. Jump Financial LLC bought a new stake in BrainsWay during the fourth quarter valued at about $207,000. Legato Capital Management LLC purchased a new position in BrainsWay in the 4th quarter worth approximately $542,000. Quadrature Capital Ltd purchased a new position in BrainsWay in the 4th quarter worth approximately $70,000. Essex Investment Management Co. LLC bought a new position in BrainsWay in the 4th quarter worth approximately $1,531,000. Finally, Tucker Asset Management LLC grew its holdings in BrainsWay by 1,686.9% during the 4th quarter. Tucker Asset Management LLC now owns 5,450 shares of the company’s stock valued at $35,000 after buying an additional 5,145 shares in the last quarter. 30.11% of the stock is currently owned by institutional investors.

BrainsWay Stock Performance

Shares of NASDAQ BWAY traded up $0.34 during midday trading on Monday, hitting $6.90. 72,455 shares of the stock traded hands, compared to its average volume of 96,327. The firm has a market capitalization of $115.02 million, a P/E ratio of -76.66 and a beta of 1.24. BrainsWay has a one year low of $2.17 and a one year high of $7.61. The firm has a 50-day moving average of $5.99 and a two-hundred day moving average of $5.97.

BrainsWay (NASDAQ:BWAY) last issued its quarterly earnings data on Wednesday, May 8th. The company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.02. BrainsWay had a negative net margin of 4.83% and a negative return on equity of 3.98%. The firm had revenue of $9.10 million for the quarter, compared to analysts’ expectations of $8.65 million. Equities analysts forecast that BrainsWay will post 0.02 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on BWAY shares. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of BrainsWay in a research note on Wednesday, June 5th. Oppenheimer upped their target price on shares of BrainsWay from $10.00 to $11.00 and gave the stock an “outperform” rating in a research report on Thursday, May 9th.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.